# The LightPath® and 68Ga-RM2 in Breast Cancer Study

> **NCT03731026** · PHASE3 · UNKNOWN · sponsor: **Lightpoint Medical Limited** · enrollment: 80 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **COMBINATION_PRODUCT:** LightPath® Imaging System and 68Ga-RM2
- **DRUG:** 68Ga-RM2

## Key facts

- **NCT ID:** NCT03731026
- **Lead sponsor:** Lightpoint Medical Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-30
- **Primary completion:** 2023-11
- **Final completion:** 2023-11
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2018-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03731026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03731026, "The LightPath® and 68Ga-RM2 in Breast Cancer Study". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT03731026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*